Sponsored Links

Wall Street Week Ahead: Correction talk gets old as rally sails along

NEW YORK - With the broad S&P 500 Index gliding once again into uncharted territory and posting four straight weeks of gains, the talk of Wall Street's rally inevitably hitting a ceiling is starting to get old.

» More Business News

Families edging out private equity in consumer deals

LONDON - From ketchup to hot drinks, family-run investment firms are shaking up the consumer deals market, squeezing out private equity players and forcing them to change strategy.

» More Small Business News

China denounces EU airline carbon law, seeks talks

BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.

» More Green Business News

Illumina says Complete Genomics rejects buyout offer

Wed Nov 21, 2012 7:28am EST

(Reuters) - Genetic sequencing company Illumina Inc (ILMN.O) said smaller peer Complete Genomics Inc GNOM.O rejected its takeover bid of about $114 million.

Complete Genomics had agreed to be bought by China's BGI-Shenzhen in September for $3.15 per share, three months after the gene sequencing company started a strategic review.

Illumina on Friday revealed its bid of $3.30 per Complete Genomics share.

In a filing on Wednesday, Illumina said its bid was superior and unlike the BGI bid, was not contingent on financing or subject to government approval as a foreign investment.

Shares of Illumina closed at $50.52 on Tuesday, while those of Complete Genomics closed at $3.09 on the Nasdaq.

(Reporting by Balaji Sridharan in Bangalore; Editing by Supriya Kurane)
Deals
Global Deals Review: 2011 Q3
Global Deals Review: 2011 Q2
Global Deals Review
Inflows Outflows
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.